India Plasma Fractionation Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Plasma fractionation is the industrial process of separating donated human blood plasma into its component proteins, which are then formulated into life-saving therapeutics. The India market represents one of the fastest-growing segments within the Asia-Pacific region, reflecting the country's expanding healthcare infrastructure and rising awareness of plasma-derived therapies. Key products include albumin for trauma and surgery support, intravenous and subcutaneous immunoglobulins for immune disorders, and coagulation factors such as Factor VIII and Factor IX for hemophilia treatment.

• •Market valued at approximately USD 1.77 billion in 2025 with projected growth to USD 1.88 billion in 2026
• •Core product categories include albumin, immunoglobulins (IVIG and SCIG), and coagulation factors (Factor VIII, Factor IX, prothrombin complex)
• •Serves critical therapeutic needs including immune deficiencies, autoimmune diseases, hemophilia, and trauma care

The market is supported by a combination of demographic, epidemiological, and healthcare-system factors. India's large and aging population is driving increased demand for plasma-derived therapeutics across a widening range of clinical indications. Expanding healthcare coverage, improved blood collection infrastructure, and growing domestic manufacturing capacity are collectively expanding supply and access. Rising prevalence of autoimmune disorders, immunodeficiency conditions, and bleeding disorders such as hemophilia further reinforce demand for immunoglobulin and coagulation factor products.

• •Growing burden of autoimmune and immunological disorders driving demand for immunoglobulin therapies including IVIG and SCIG
• •Expanding healthcare infrastructure and government initiatives supporting plasma collection and fractionation capacity
• •Increasing diagnosis and treatment of hemophilia and other coagulation disorders boosting demand for Factor VIII and Factor IX products

The market is segmented by product type, with albumin, immunoglobulins, and coagulation factors representing the primary categories. Within immunoglobulins, intravenous (IVIG) and subcutaneous (SCIG) formulations serve distinct clinical and patient-preference profiles. Coagulation factors, including Factor VIII for hemophilia A and Factor IX for hemophilia B, address specific bleeding disorder indications. The Asia-Pacific region is a significant and expanding market globally, with India positioned as a key contributor due to its large patient population and evolving healthcare ecosystem.

• •Immunoglobulins segment (IVIG and SCIG) constitutes the largest and fastest-growing product category
• •Coagulation factors (Factor VIII, Factor IX, prothrombin complex) serve the hemophilia and bleeding disorder treatment market
• •Asia-Pacific region is a major and expanding market, with India as one of the key national markets within the region

What are the recent trends and outlook?

The plasma fractionation market globally is expected to continue growing through the 2030s, supported by aging populations, broadening clinical applications of plasma-derived therapies, and increasing adoption in emerging markets including India. Technological advancements in fractionation processes and purification methods are improving product yields and safety profiles. Subcutaneous immunoglobulin (SCIG) formulations are gaining share due to improved patient convenience compared to traditional intravenous administration. Long-term outlook remains positive as unmet medical needs in rare diseases and immune disorders drive continued investment in plasma collection and manufacturing capacity.

• •Global plasma fractionation market projected to grow significantly through 2030, with the broader market estimated between USD 35 billion and USD 58 billion depending on scope and methodology
• •SCIG (subcutaneous immunoglobulin) formulations are increasingly favored for home administration and improved quality of life
• •Emerging markets including India are expected to contribute meaningfully to growth as healthcare access and domestic manufacturing expand